Biotech Values

[DewDiligence]

NCCN gives Avastin in breast cancer a tepid recommendation, which might be enough to ensure reimbursement if the FDA does not rescind the approval in this indication (emphasis below added my me):

http://finance.yahoo.com/news/NCCN-Guidelines-for-Breast-bw-1308147429.html?x=0&.v=1

The NCCN Guidelines Panel for Breast Cancer affirmed its existing recommendation of bevacizumab in combination with paclitaxel as an appropriate therapeutic option for metastatic breast cancer with the evidence designation 2A meaning that it is based on lower level evidence and uniform agreement of the panel as to its appropriateness.

The Panel revised the related footnote; it now states, “Randomized clinical trials in metastatic breast cancer document that the addition of bevacizumab to some first or second line chemotherapy agents modestly improves time to progression and response rates but does not improve overall survival. The time to progression impact may vary among cytotoxic agents and appears greatest with bevacizumab in combination with weekly paclitaxel.”